Skip to main content

Advertisement

SpringerLink
Log in

“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015

  • Meeting Report
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

AKT:

Protein kinase B

ALC:

Absolute lymphocyte count

ALK:

Anaplastic lymphoma kinase

ANC:

Absolute neutrophil count

ARG1:

Arginase 1

AZA:

5-Aza-2′-deoxycitidine

BRAFi:

BRAF inhibitor

BsAb:

Bispecific antibody

CCL2:

C-C motif ligand 2

CCR2:

C-C chemokine receptor type 2

ccRCC:

Renal cell carcinoma

CD40-L:

CD40 ligand

CIMT:

Association for Cancer Immunotherapy

CRC:

Colorectal cancer

CTA:

Cancer testis antigen

CXCL:

Chemokine ligand

CXCL8:

C-X-C motif ligand 8

Cyp46a1:

Cholesterol 24 hydroxylase

DFS:

Disease-free survival

dNLR:

Derived neutrophil-to-lymphocyte ratio

DTIC:

Dacarbazine

EAIO:

European Alliance for Immuno-Oncology

EATI:

European Academy of Tumor Immunology

ECM:

Extracellular matrix

EMT:

Epithelial-to-mesenchymal transition

ESCI:

European Society for Clinical Investigation

exo-MDC:

Melanoma-derived exosome

FOLFIRI:

5-Fluorouracile, leucovorin, irinotecan

FTM:

Fotemustine

GEIT:

Grupo Español de Inmunoterapia

GETICA:

El Grupo Español de Terapias Inmuno-Biológicas en Cáncer

Grp94:

Glucose-regulated protein 94

HCC:

Hepatocellular carcinoma

hPSMA:

Human prostate-specific membrane antigen

HSC:

Hematopoietic stem cell

IL22BP:

Interleukin 22 binding protein

KIR:

Killer cell receptor

mCRC:

Metastatic colorectal cancer

Melan-A:

Melanoma antigen A

miRNA:

Micro-RNA

MM:

Metastatic melanoma

NGS:

Next-generation sequencing

NKG2DL:

Natural-killer group 2, member D ligand

NOS2:

Nitric oxide synthase 2

NSCLC:

Non-small cell lung cancer

PFS:

Progression-free survival

PPI:

Proton pump inhibitor

PTX3:

Pentraxin 3

RORC1/RORγ:

Retinoic-acid-related orphan receptor

SGI-110:

Guadecitabine

SPARC:

Secreted protein acidic and rich in cysteine

T-reg:

Regulatory T lymphocyte

WT:

Wild type

TAM:

Tumor-associated macrophage

TAP-1:

Transporter associated with antigen processing 1

TFLN:

Ipsilateral tumor-free lymph node

TILN:

Tumor infiltrated lymph node

TLS:

Tertiary lymphoid structure

TRAIL-R2:

TNF-related apoptosis-inducing ligand receptor 2

Acknowledgments

This meeting was organized in collaboration with the Board of Directors of NIBIT.

NIBIT participants

Vincenzo Bronte, Verona University Hospital, Verona, Italy; Barbara Seliger, Martin Luther University, Halle-Wittenberg, Germany; Licia Rivoltini, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Antonio Sica, Humanitas Clinical and Research Center, Milan, Italy; Mario Leonardo Squadrito, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Hans-Georg Rammensee, University of Tübingen, Tübingen, Germany; Ugur Sahin, TRON—Translational Cancer Center, Johannes Gutenberg University, Mainz, Germany; Gerold Schuler, Friedrich-Alexander University, Erlangen, Germany; Zlatko Trajanoski Medical University of Innsbruck, Innsbruck, Austria; Wolf H. Fridman, Cordeliers Research Centre, University Paris Descartes, Paris, France; Francesco M. Marincola, Sidra Medical and Research Center, Doha, Qatar; Andrea Anichini, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Arianna Calcinotto, Istituto Scientifico San Raffaele, Milan, Italy; Samuel Huber, University Medical Center Hamburg-Eppendorf, Germany; Chiara Pozzi, Istituto Europeo di Oncologia, Milan, Italy; Gianfranca Corna, Istituto Scientifico San Raffaele, Milan, Italy; Pierre Coulie, de Duve Institute, Bruxelles, Belgium; Mariangela Figini, Fondazione IRCCS, Milano, Italy; Luana Calabrò, University Hospital of Siena, Siena, Italy; Soldano Ferrone, Massachusetts General Hospital Harvard Medical School, Boston, USA; Carla Buccione, Istituto Superiore di Sanità, Rome, Italy; Maria Tagliamonte, Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy; Christoph Huber, University of Mainz, Germany; Michael Giordano, Bristol-Myers Squibb, New York, USA; Ramy Ibrahim Astra Zeneca, Gaithersburg, USA; Jean-Marie Cuillerot, Merck & Co., Inc., New York; USA; Elliot Chartash, EMD-Serono, Boston, MA, USA; Mohammad Azab, Astex/Otsuka, Pleasenton, USA; Mario P. Colombo, IRCSS Foundation of the Istituto Nazionale dei Tumori, Milan, Italy; Ennio Carbone, University of Catanzaro “Magna Graecia,” Catanzaro, Italy; Chiara Martinoli, European Institute of Oncology, Milan, Italy; Paola Nistico’, Regina Elena National Cancer Institute, Rome, Italy; Cecilia Garlanda, Humanitas Clinical and Research Center, Milan, Italy; Anna Maria Di Giacomo, University Hospital of Siena, Italy; Per thor Straten, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark; Giacomo Oliveira, Istituto Scientifico San Raffaele, Milan, Italy; Lorenzo Moretta, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy; Gaia Zuccolotto, University of Padua, Padua, Italy; and Silvio Monfardini, Istituto Palazzolo-Don Gnocchi, Milan, Italy.

Author information

Authors and Affiliations

  1. Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, V.le Bracci, 16, Siena, Italy

    Michele Maio, Erica Bertocci, Carolina Fazio, Carla Chiarucci, Ornella Cutaia, Elisa Scala, Gianluca Giacobini, Maria Fortunata Lofiego, Ester Fonsatti, Cristina Maccalli & Giorgio Parmiani

  2. Network Italiano per la bioterapia dei tumori (NIBIT), Siena, Italy

    Michele Maio, Cristina Maccalli & Giorgio Parmiani

  3. University of Siena, Siena, Italy

    Carolina Fazio, Carla Chiarucci, Ornella Cutaia, Gianluca Giacobini & Maria Fortunata Lofiego

  4. Research Branch, Sidra Medical and Research Center, Doha, Qatar

    Hugues J. M. G. Nicolay

Authors
  1. Michele Maio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erica Bertocci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carolina Fazio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carla Chiarucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ornella Cutaia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elisa Scala
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gianluca Giacobini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maria Fortunata Lofiego
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ester Fonsatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Cristina Maccalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hugues J. M. G. Nicolay
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Giorgio Parmiani
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

NIBIT

  • Andrea Anichini
  • , Anna Maria Di Giacomo
  • , Antonio Sica
  • , Arianna Calcinotto
  • , Barbara Seliger
  • , Carla Buccione
  • , Cecilia Garlanda
  • , Chiara Martinoli
  • , Chiara Pozzi
  • , Christoph Huber
  • , Elliot Chartash
  • , Ennio Carbone
  • , Francesco M. Marincola
  • , Gaia Zuccolotto
  • , Gerold Schuler
  • , Giacomo Oliveira
  • , Gianfranca Corna
  • , Hans-Georg Rammensee
  • , Jean-Marie Cuillerot
  • , Licia Rivoltini
  • , Lorenzo Moretta
  • , Luana Calabrò
  • , Maria Tagliamonte
  • , Mariangela Figini
  • , Mario Leonardo Squadrito
  • , Mario P. Colombo
  • , Michael Giordano
  • , Mohammad Azab
  • , Paola Nistico’
  • , Per thor Straten
  • , Pierre Coulie
  • , Ramy Ibrahim
  • , Samuel Huber
  • , Silvio Monfardini
  • , Soldano Ferrone
  • , Ugur Sahin
  • , Vincenzo Bronte
  • , Wolf H. Fridman
  •  & Zlatko Trajanoski

Corresponding author

Correspondence to Michele Maio.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest. Michele Maio and Giorgio Parmiani: local and scientific organizing committee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maio, M., Bertocci, E., Fazio, C. et al. “Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015. Cancer Immunol Immunother 65, 1423–1431 (2016). https://doi.org/10.1007/s00262-016-1899-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-016-1899-1

Keywords

Search

Navigation